101 related articles for article (PubMed ID: 27793921)
21. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability.
Bialer M; Midha KK
Epilepsia; 2010 Jun; 51(6):941-50. PubMed ID: 20384761
[TBL] [Abstract][Full Text] [Related]
22. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C
Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
Ma MK; Zamboni WC; Radomski KM; Furman WL; Santana VM; Houghton PJ; Hanna SK; Smith AK; Stewart CF
Clin Cancer Res; 2000 Mar; 6(3):813-9. PubMed ID: 10741701
[TBL] [Abstract][Full Text] [Related]
24. Irinotecan (CPT-11) metabolism and disposition in cancer patients.
Sparreboom A; de Jonge MJ; de Bruijn P; Brouwer E; Nooter K; Loos WJ; van Alphen RJ; Mathijssen RH; Stoter G; Verweij J
Clin Cancer Res; 1998 Nov; 4(11):2747-54. PubMed ID: 9829738
[TBL] [Abstract][Full Text] [Related]
25. [Generic drugs: we must cut pharmaceutical spending but undertaking drug quality].
Carrillo Norte JA; Postigo Mota S
Rev Enferm; 2012 Feb; 35(2):10-9. PubMed ID: 22670381
[TBL] [Abstract][Full Text] [Related]
26. Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation.
Wang W; Ghandi A; Liebes L; Louie SG; Hofman FM; Schönthal AH; Chen TC
J Neurosurg; 2011 Mar; 114(3):689-94. PubMed ID: 20415520
[TBL] [Abstract][Full Text] [Related]
27. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice.
Stewart CF; Zamboni WC; Crom WR; Houghton PJ
Cancer Chemother Pharmacol; 1997; 40(3):259-65. PubMed ID: 9219511
[TBL] [Abstract][Full Text] [Related]
28. [Generic drugs].
Delporte JP
Rev Med Liege; 2002 Jan; 57(1):13-22. PubMed ID: 11899492
[TBL] [Abstract][Full Text] [Related]
29. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
[TBL] [Abstract][Full Text] [Related]
30. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines.
Chu XY; Suzuki H; Ueda K; Kato Y; Akiyama S; Sugiyama Y
J Pharmacol Exp Ther; 1999 Feb; 288(2):735-41. PubMed ID: 9918583
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
[TBL] [Abstract][Full Text] [Related]
32. Generic Selection Criteria for Safety and Patient Benefit [IV] - Physicochemical and pharmaceutical properties of brand-name and generic ketoprofen tapes.
Wada Y; Kihara M; Nozawa M; Shimokawa K; Ishii F
Drug Discov Ther; 2015 Jun; 9(3):229-33. PubMed ID: 26193946
[TBL] [Abstract][Full Text] [Related]
33. Bioequivalence review for drug interchangeability.
Chow SC; Shao J
J Biopharm Stat; 1999 Aug; 9(3):485-97. PubMed ID: 10473033
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
Slatter JG; Schaaf LJ; Sams JP; Feenstra KL; Johnson MG; Bombardt PA; Cathcart KS; Verburg MT; Pearson LK; Compton LD; Miller LL; Baker DS; Pesheck CV; Lord RS
Drug Metab Dispos; 2000 Apr; 28(4):423-33. PubMed ID: 10725311
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
Klein CE; Gupta E; Reid JM; Atherton PJ; Sloan JA; Pitot HC; Ratain MJ; Kastrissios H
Clin Pharmacol Ther; 2002 Dec; 72(6):638-47. PubMed ID: 12496745
[TBL] [Abstract][Full Text] [Related]
36. Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.
Nakajima TE; Yanagihara K; Takigahira M; Yasunaga M; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Mihara K; Ochiya T; Matsumura Y
Cancer Res; 2008 Nov; 68(22):9318-22. PubMed ID: 19010905
[TBL] [Abstract][Full Text] [Related]
37. A comparison of active ingredients and preservatives between brand name and generic topical glaucoma medications using liquid chromatography-tandem mass spectrometry.
Kahook MY; Fechtner RD; Katz LJ; Noecker RJ; Ammar DA
Curr Eye Res; 2012 Feb; 37(2):101-8. PubMed ID: 22040280
[TBL] [Abstract][Full Text] [Related]
38. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
39. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
[TBL] [Abstract][Full Text] [Related]
40. In vivo evaluation of irinotecan-loaded QuadraSphere microspheres for use in chemoembolization of VX2 liver tumors.
Tanaka K; Maeda N; Osuga K; Higashi Y; Hayashi A; Hori Y; Kishimoto K; Morii E; Ohashi F; Tomiyama N
J Vasc Interv Radiol; 2014 Nov; 25(11):1727-35.e1. PubMed ID: 25239839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
